The Wits HIV Research Group (WHRG) is a well-organized, highly effective Clinical Trial Unit (CTU) with an international reputation built on the successful conduct of NIH sponsored multi-centre trails, as well as its work with other international research groups. The WHRG consists of five Clinical Research Sites (CRSs) supported by a coordinating centre. This group has the capacity to undertake research in 5 high priority areas of HIV clinical trial research. The priority areas include Optimization of Clinical Management of HIV;Drug Development and Translational Research;HIV Prevention;Prevention of Mother to Child Transmission of HIV;HIV Vaccine Research and Development;and Microbicide Development. The CTU will link with five leadership networks (ACTG, IMPAACT, Microbicide Network, HVTN and PTN), maximizing scientific and recruitment opportunities by effectively integrating prevention, vaccine and therapeutic clinical trials in children, adolescents and adults. The unit will build on an established track record of the University of the Witwatersrand ACTU (Site#11101), PACTG (Site#8051), HPTN (Site#001-7) and a track record of international collaboration for microbicide research. In addition to our excellent record of research, this CTU contains four sites with letters confirming their status as selected sites for collaboration on four networks. The WHRG has a talented and skilled group of senior investigators with international reputations supported by enthusiastic research teams who are committed to HIV prevention in resource poor settings and the identification and management of acute HIV infections. The research team of the CTU has demonstrated an ability to work collaboratively with each other in all facets of the five networks and on PEPFAR initiatives. It is our aim to create a synergistic, pluri-potential CTU that is able to implement world-class research. In so doing, we also aim to achieve financial and operational efficiencies through centralizing and consolidating critical clinical research functions such as staff training, protocol implementation, regulatory compliance, IRB submission, pharmacy importation and data and quality management. The WHRG has close collaboration and support from the local, provincial and national Departments of Health, as well as from its own institutions. ADMINISTRATIVE COMPONENT:

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI069463-06
Application #
8215950
Study Section
Special Emphasis Panel (ZAI1-BLG-A (M1))
Program Officer
Germuga, Donna E
Project Start
2007-03-15
Project End
2013-01-31
Budget Start
2012-02-01
Budget End
2013-01-31
Support Year
6
Fiscal Year
2012
Total Cost
$2,250,104
Indirect Cost
$509,307
Name
Wits Health Consortium (Pty), Ltd
Department
Type
DUNS #
639391218
City
Johannesburg
State
Country
South Africa
Zip Code
De Boni, Raquel B; Zheng, Lu; Rosenkranz, Susan L et al. (2016) Binge drinking is associated with differences in weekday and weekend adherence in HIV-infected individuals. Drug Alcohol Depend 159:174-80
Mave, Vidya; Erlandson, Kristine M; Gupte, Nikhil et al. (2016) Inflammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected Adults. J Infect Dis 214:65-72
Luetkemeyer, Anne F; Firnhaber, Cynthia; Kendall, Michelle A et al. (2016) Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings. Clin Infect Dis 62:1081-8
Robertson, K; Jiang, H; Evans, S R et al. (2016) International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271. J Neurovirol 22:472-8
La Rosa, Alberto M; Harrison, Linda J; Taiwo, Babafemi et al. (2016) Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. Lancet HIV 3:e247-58
Fogel, Jessica M; Hudelson, Sarah E; Ou, San-San et al. (2016) Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial. J Acquir Immune Defic Syndr 72:304-9
van der Straten, Ariane; Brown, Elizabeth R; Marrazzo, Jeanne M et al. (2016) Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study. J Int AIDS Soc 19:20642
Hosseinipour, Mina C; Bisson, Gregory P; Miyahara, Sachiko et al. (2016) Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. Lancet 387:1198-209
Castillo-Mancilla, Jose R; Aquilante, Christina L; Wempe, Michael F et al. (2016) Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). J Antimicrob Chemother 71:1609-18
Riddler, Sharon A; Husnik, Marla; Gorbach, Pamina M et al. (2016) Long-term follow-up of HIV seroconverters in microbicide trials - rationale, study design, and challenges in MTN-015. HIV Clin Trials 17:204-11

Showing the most recent 10 out of 67 publications